Effect of DASH diet in patients with non-alcoholic fatty liver disease

The effect of DASH diet on hepatic fibrosis, hepatic steatosis, liver enzymes, insulin resistance and oxidative stress in patients with non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170117032026N3

Enrollment

Registered

2022-02-06

Start date

2022-01-21

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease

Interventions

Intervention 1: DASH (Dietary Approaches to Stop Hypertension) diet. This diet contains 52 to 55% carbohydrates, 16 to 18% protein and 30% fat. The DASH diet is rich in fruits, vegetables, whole grain

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. People 18 to 70 years old 2. People with body mass index 25 to 40 3. Diagnosis based on liver fibroscan 4. Have informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation 2. Hereditary hemochromatosis 3. History of gingival or gastroplasty bypass surgery 4. Use of hepatotoxic drugs such as calcium channel blockers and high doses of synthetic estrogens 5. Patients with hypothyroidism 6. Cushing's syndrome and 7. Kidney failure Kidney stones 8. Cardiovascular disease 9. People with a history of hepatitis B and C 10. Wilson disease

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Aspartat transaminase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Hepatic fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;Hepatic steatosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.	—

Measure

Time frame

Alanine Aminotransferase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Aspartat transaminase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Hepatic fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;Hepatic steatosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.

—

Secondary

Measure	Time frame
Insulin. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Special kit.;Total antioxidant capacity. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Catalase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Superoxide dismutase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;PAB. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;High sensitivity C-reactive protein. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Triglyceride. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Total cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;High density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Low density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Homeostatic model assessment of insulin resistance. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Formula.;Insulin sensitivity check index. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Formula.;Weight, fat mass, fat free mass, RMR, body mass index and visceral fat. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Omron digital Scale.;Waist,Hip circumference. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Meter.;Diastolic blood pressure. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Sphygmomanometer.;Systolic blood pressure. Timepoint: Before intervention an	—

Measure

Time frame

Insulin. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Special kit.;Total antioxidant capacity. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Catalase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Superoxide dismutase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;PAB. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;High sensitivity C-reactive protein. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Triglyceride. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Total cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;High density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Low density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kit.;Homeostatic model assessment of insulin resistance. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Formula.;Insulin sensitivity check index. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Formula.;Weight, fat mass, fat free mass, RMR, body mass index and visceral fat. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Omron digital Scale.;Waist,Hip circumference. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Meter.;Diastolic blood pressure. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Sphygmomanometer.;Systolic blood pressure. Timepoint: Before intervention an

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahdie Hoseinzadeh

Yazd University of Medical Sciences

hoseinzade.mahdie@gmail.com+98 35 3149 2232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026